Impact of leukocyte function-associated antigen-1 blockade on endogenous allospecific t cells to multiple minor histocompatibility antigen mismatched cardiac allograft

Transplantation

Volumn 99, Issue 12, 2015, Pages 2485-2493

  Kwun, Jean ^a,b,c,d   Farris, Alton B ^b   Song, Hyunjin ^a   Mahle, William T ^b,c   Burlingham, William J ^e   Knechtle, Stuart J ^a,b,c,d  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

H13 ANTIGEN; H28 ANTIGEN; H4 ANTIGEN; H60 ANTIGEN; H7 ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LFA 1; UNCLASSIFIED DRUG; ANTI-LFA-1 MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTERIOSCLEROSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CD8+ T LYMPHOCYTE; CELL EXPANSION; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; HEART MUSCLE FIBROSIS; HEART TRANSPLANTATION; IMMUNOREGULATION; LYMPHOCYTIC INFILTRATION; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; ALLOGRAFT; ALLOTRANSPLANTATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ALLOGRAFTS; ANIMALS; ANTIBODIES, MONOCLONAL; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MINOR HISTOCOMPATIBILITY ANTIGENS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84946581113     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000805     Document Type: Article

References (33)

1. Fawcett J, Holness CL, NeedhamLA, et al.Molecular cloning of ICAM-3, a third ligand for LFA-1, constitutively expressed on resting leukocytes. Nature. 1992; 360: 481-484.
2. Shamri R, Grabovsky V, Gauguet JM, et al. Lymphocyte arrest requires instantaneous induction of an extended LFA-1 conformation mediated by endothelium-bound chemokines. Nat Immunol. 2005; 6: 497-506.
3. Shimizu Y. LFA-1: more than just T cell Velcro. Nat Immunol. 2003; 4: 1052-1054.
4. Springer TA, Dustin ML, Kishimoto TK, et al. The lymphocyte functionassociated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. Annu Rev Immunol. 1987; 5: 223-252.
5. Lee KH, Holdorf AD, Dustin ML, et al. T cell receptor signaling precedes immunological synapse formation. Science. 2002; 295: 1539-1542.
6. Bromley SK, Dustin ML. Stimulation of naive T-cell adhesion and immunological synapse formation by chemokine-dependent and -independent mechanisms. Immunology. 2002; 106: 289-298.
7. Freiberg BA, Kupfer H, Maslanik W, et al. Staging and resetting T cell activation in SMACs. Nat Immunol. 2002; 3: 911-917.
8. Isobe M, Yagita H, Okumura K, et al. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science. 1992; 255: 1125-1127.
9. Nakakura EK, Shorthouse RA, Zheng B, et al. Long-term survival of solid organ allografts by brief anti-lymphocyte function-associated antigen-1 monoclonal antibody monotherapy. Transplantation. 1996; 62: 547-552.
10. Setoguchi K, Schenk AD, Ishii D, et al. LFA-1 antagonism inhibits early infiltration of endogenous memory CD8 T cells into cardiac allografts and donor-reactive T cell priming. Am J Transplant. 2011; 11: 923-935.
11. Reisman NM, Floyd TL, Wagener ME, et al. LFA-1 blockade induces effector and regulatory T-cell enrichment in lymph nodes and synergizes with CTLA-4Ig to inhibit effector function. Blood. 2011; 118: 5851-5861.
12. Kwun J, Malarkannan S, Burlingham WJ, et al. Primary vascularization of the graft determines the immunodominance of murine minor H antigens during organ transplantation. J Immunol. 2011; 187: 3997-4006.
13. Kwun J, Oh BC, Gibby AC, et al. Patterns of de novo allo B cells and antibody formation in chronic cardiac allograft rejection after Alemtuzumab treatment. Am J Transplant. 2012; 12: 2641-2651.
14. McGavern DB, Christen U, Oldstone MB. Molecular anatomy of antigenspecific CD8(+) T cell engagement and synapse formation in vivo. Nat Immunol. 2002; 3: 918-925.
15. Skinner PJ, Daniels MA, Schmidt CS, et al. Cutting edge: in situ tetramer staining of antigen-specific T cells in tissues. J Immunol. 2000; 165: 613-617.
16. Dickinson AM, Wang XN, Sviland L, et al. In situ dissection of the graftversus- host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med. 2002; 8: 410-414.
17. Kwun J, Knechtle SJ, Hu H. Determination of the functional status of alloreactive T cells by interferon-gamma kinetics. Transplantation. 2006; 81: 590-598.
18. Chong AS, Alegre ML, Miller ML, et al. Lessons and limits of mouse models. Cold Spring Harb Perspect Med. 2013; 3: a015495.
19. Kwun J, Hu H, Schadde E, et al. Altered distribution of H60 minor H antigen-specific CD8 T cells and attenuated chronic vasculopathy in minor histocompatibility antigen mismatched heart transplantation in Cxcr3-/- mouse recipients. J Immunol. 2007; 179: 8016-8025.
20. Kwun J, Knechtle SJ. Overcoming chronic rejection-can it B? Transplantation. 2009; 88: 955-9561.
21. Choi EY, Christianson GJ, Yoshimura Y, et al. Immunodominance of H60 is caused by an abnormally high precursor T cell pool directed against its unique minor histocompatibility antigen peptide. Immunity. 2002; 17: 593-603.
22. Choi EY, Yoshimura Y, Christianson GJ, et al. Quantitative analysis of the immune response to mouse non-MHC transplantation antigens in vivo: the H60 histocompatibility antigen dominates over all others. J Immunol. 2001; 166: 4370-9.
23. Komatsu M, Mammolenti M, Jones M, et al. Antigen-primed CD8+ T cells can mediate resistance, preventing allogeneic marrow engraftment in the simultaneous absence of perforin-, CD95L-, TNFR1-, and TRAIL-dependent killing. Blood. 2003; 101: 3991-3999.
24. Zimmerman Z, Shatry A, Deyev V, et al. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways. Biol Blood Marrow Transplant. 2005; 11: 576-586.
25. Zimmerman ZF, Levy RB. MiHA reactive CD4 and CD8 T-cells effect resistance to hematopoietic engraftment following reduced intensity conditioning. Am J Transplant. 2006; 6: 2089-2098.
26. de Witte MA, Toebes M, Song JY, et al. Effective graft depletion of MiHAg T-cell specificities and consequences for graft-versus-host disease. Blood. 2007; 109: 3830-3838.
27. Fischer A, Durandy A, Sterkers G, et al. Role of the LFA-1 molecule in cellular interactions required for antibody production in humans. J Immunol. 1986; 136: 3198-3203.
28. Howard DR, Eaves AC, Takei F. Lymphocyte function-associated antigen (LFA-1) is involved in B cell activation. J Immunol. 1986; 136: 4013-4018.
29. Monks CR, Freiberg BA, Kupfer H, et al. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature. 1998; 395: 82-86.
30. Grakoui A, Bromley SK, Sumen C, et al. The immunological synapse: a molecularmachine controlling Tcell activation. Science. 1999; 285: 221-227.
31. Apostolou I, von Boehmer H. In vivo instruction of suppressor commitment in naive T cells. J ExpMed. 2004; 199: 1401-1408.
32. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009; 10: 816-824.
33. Vincenti F, Mendez R, Pescovitz M, et al. A phase I/II randomized openlabel multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant. 2007; 7: 1770-1777.